Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 714 of 5804
-
Heart valve showdown: which TAVR device wins for small aortas?
Disease control OngoingThe purpose of this trial is to generate clinical evidence on valve safety and performance of self-expanding (SE) versus balloon-expandable (BE) transcatheter aortic valve replacement (TAVR) in subjects with a small aortic annulus and symptomatic severe native aortic stenosis. A…
Phase: NA • Sponsor: Medtronic Cardiovascular • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
Chikungunya vaccine shows promise for Long-Term protection
⭐️ VACCINE ⭐️ OngoingIn this open-label Phase 3b, single arm trial, persistence of antibodies and long term safety will be evaluated in up to 375 participants rolled over from trial VLA1553-301 (NCT number: NCT04546724).
Phase: PHASE3 • Sponsor: Valneva Austria GmbH • Aim: ⭐️ VACCINE ⭐️
Last updated Jul 11, 2026 00:00 UTC
-
New pill could help men with erectile dysfunction achieve and maintain erections
Disease control CompletedThis is a multicenter, randomized, double blind, placebo-controlled, parallel design study to evaluate the efficacy and safety of Tunodafil Hydrochloride Tablets in men with erectile dysfunction.
Phase: PHASE3 • Sponsor: Yangtze River Pharmaceutical Group Co., Ltd. • Aim: Disease control
Last updated Jul 11, 2026 00:00 UTC
-
Inhaled antibiotic shows promise against stubborn lung infection
Disease control CompletedThe main objective of this study is to evaluate the efficacy of ALIS (amikacin liposome inhalation suspension) + background regimen (azithromycin \[AZI\] + ethambutol \[ETH\]) compared to the ELC (empty liposome control) + background regimen on participant-reported respiratory sy…
Phase: PHASE3 • Sponsor: Insmed Incorporated • Aim: Disease control
Last updated Jun 27, 2026 09:01 UTC
-
New hope for kids with rare blood cancer: targeted drug trial launches
Disease control Recruiting nowProspective, interventional, open, randomized, single-center, non-commercial clinical trial to optimize treatment and dosage of vemurafenib in juvenile patients with histiocytosis resistant to conventional therapy and in whom the BRAF gene mutation has been found.
Phase: PHASE2 • Sponsor: Anna Raciborska • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
New heart attack procedures aim to save more lives and prevent repeat attacks
Disease control Recruiting nowThe purpose of is study is to investigate whether ischemic postconditioning (iPOST) and intravascular ultrasound-guided (IVUS) percutaneous coronary intervention (PCI) improve the clinical outcome of patients with ST-segment elevation myocardial infarction treated with primary PC…
Phase: NA • Sponsor: Thomas Engstrom • Aim: Disease control
Last updated Jun 27, 2026 12:02 UTC
-
Diabetes drug semaglutide tested as potential treatment for fatty liver disease NASH
Disease control OngoingSemaglutide is a medicine studied in patients with NASH. Semaglutide is a well-known medicine, which is already used by doctors to treat type 2 diabetes in many countries. Participants will either get semaglutide or a dummy medicine - which treatment participants get is decided …
Phase: PHASE3 • Sponsor: Novo Nordisk A/S • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
Gene test could tailor chemo for pancreatic cancer patients
Disease control Recruiting nowThis is an open-label, phase II study in patients with resectable and borderline resectable pancreatic cancer.
Phase: PHASE2 • Sponsor: Medical College of Wisconsin • Aim: Disease control
Last updated Jun 27, 2026 09:11 UTC
-
New combo therapy aims to shrink tumors in hard-to-treat cancers
Disease control OngoingBasket trial concept to independently and simultaneously assess the effects of the association of atezolizumab + BDB001 + radiotherapy in multiple solid tumors.
Phase: PHASE2 • Sponsor: Institut Bergonié • Aim: Disease control
Last updated Jul 26, 2026 00:00 UTC
-
Could an existing eczema drug help a rare skin condition?
Disease control OngoingNummular eczema (NE) is an idiopathic chronic inflammatory skin disease that occurs throughout all life periods. Diagnosis is made primarily clinically in correlation with histological findings. Treatment of NE is difficult. Standard treatment consists of the use of emollients, t…
Phase: PHASE2 • Sponsor: Technical University of Munich • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC
-
New hope for tough lung cancers: DS-1062a shows promise in early trial
Disease control CompletedThis is a study of the efficacy, pharmacokinetics, and safety of DS-1062a in participants with advanced or metastatic non-small cell lung cancer (NSCLC) with known actionable genomic alterations.
Phase: PHASE2 • Sponsor: Daiichi Sankyo • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
New hope for lymphoma patients after CAR T-Cell failure
Disease control CompletedThis study is a multicenter phase II trial including 2 cohorts of patients in Refractory/Relapse disease at least 1 month after CAR T-cells therapy: * cohort 1: DLBCL patients * cohort 2: PMBL, mantle cell lymphoma, transformed indolent NHL (t-iNHL) or iNHL CAR T-cells Refractor…
Phase: PHASE2 • Sponsor: The Lymphoma Academic Research Organisation • Aim: Disease control
Last updated Jun 27, 2026 11:01 UTC
-
New hope for kids with aggressive brain cancer: drug aims to stop relapse
Disease control Recruiting nowDifluoromethylornithine (DFMO) will be used in an open label, multicenter, study as Maintenance Therapy for Molecular High Risk/Very High Risk and Relapsed/Refractory Medulloblastoma.
Phase: PHASE2 • Sponsor: Giselle Sholler • Aim: Disease control
Last updated Jun 27, 2026 12:25 UTC
-
New combo therapy shows promise for Tough-to-Treat colorectal cancer
Disease control CompletedThe purpose of this study is to assess the safety and efficacy of lenvatinib (MK-7902/E7080) in combination with pembrolizumab (MK-3475) in participants with metastatic colorectal cancer. The study will also compare lenvatinib plus pembrolizumab with the standard of care treatmen…
Phase: PHASE3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 27, 2026 09:02 UTC
-
Could a love hormone help veterans beat alcohol addiction and PTSD?
Symptom relief OngoingThe primary objective of the proposed Stage II study is to examine the efficacy of oxytocin (OT) as compared to placebo in reducing (1) alcohol use disorder (AUD) symptoms, and (2) post-traumatic stress disorder (PTSD) symptoms among Veterans receiving COPE therapy (Concurrent Tr…
Phase: PHASE2 • Sponsor: Medical University of South Carolina • Aim: Symptom relief
Last updated Jun 27, 2026 12:05 UTC
-
Experimental combo targets HPV-Driven head and neck tumors
Disease control CompletedVERSATILE-002 is a Phase 2, open-label, multicenter study of the efficacy and safety of PDS0101 administered in combination with pembrolizumab in adults with HPV16 and PD-L1 positive recurrent or metastatic head and neck squamous cell carcinoma (HNSCC).
Phase: PHASE2 • Sponsor: PDS Biotechnology Corp. • Aim: Disease control
Last updated Jun 27, 2026 07:53 UTC
-
Immune cell therapy shows promise for Tough-to-Treat lymphoma
Disease control CompletedAB-101 is an off-the shelf, allogeneic cell product made of "natural killer" cells, also called NK cells. White blood cells are part of the immune system and NK cells are a type of white blood cell that are known to kill cancer cells. This clinical trial will enroll patients wit…
Phase: PHASE1, PHASE2 • Sponsor: Artiva Biotherapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
New injection shows promise for long-term prevention of rare swelling disorder
Disease control CompletedThis phase 3b study will evaluate long-term safety and efficacy of CSL312 (also known as garadacimab) when administered subcutaneously (SC)
Phase: PHASE3 • Sponsor: CSL Behring • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
Cancer-Killing virus injected directly into tumors shows promise in Mid-Stage trial
Disease control OngoingAdAPT-001 is an oncolytic virus that is injected directly into the tumor or via intraarterial administration. The purpose of this study is to find out if AdAPT-001 is safe and tolerable. The next step is to find out if AdAPT-001 if efficacious with or without a checkpoint inhibit…
Phase: PHASE2 • Sponsor: EpicentRx, Inc. • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
Mobile TB testing vans could catch hidden cases in slums
Knowledge-focused CompletedTB remains the foremost infectious disease killer globally. A startling statistic is that two out of every five TB cases globally (40%) remain undiagnosed and untreated. These 'missed' or undiagnosed cases are disproportionately concentrated in large peri-urban 'slums' and inform…
Phase: NA • Sponsor: University of Cape Town • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:30 UTC